• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Korean Med Sci . Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging

tetano

Editor, Senior Moderator
J Korean Med Sci


. 2023 Mar 20;38(11):e87.
doi: 10.3346/jkms.2023.38.e87.
Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study


Yoo-Yeon Kim[SUP] #[/SUP][SUP] 1 [/SUP], Young June Choe[SUP] #[/SUP][SUP] 2 [/SUP], Jia Kim[SUP] 1 [/SUP], Ryu Kyung Kim[SUP] 1 [/SUP], Eun Jung Jang[SUP] 1 [/SUP], Hyeryeon Lee[SUP] 1 [/SUP], Seonju Yi[SUP] 1 [/SUP], Sangwon Lee[SUP] 1 [/SUP], Young-Joon Park[SUP] 3 [/SUP]



Affiliations

Abstract

National cohort data collected during the coronavirus disease 2019 (COVID-19) delta and omicron periods in Korea revealed a lower risk of severe infection in recipients of three doses of the COVID-19 vaccine (adjusted odds ratio [aOR], 0.05-0.08). The risk of death was reduced during the omicron period compared to the delta period (aOR, 0.75; 95% confidence interval, 0.67-0.84).

Keywords: Booster; COVID-19; Coronavirus; SARS-CoV-2; Vaccine.
 
Back
Top Bottom